Skip to main content
. 2021 Aug 23;112(10):4404–4417. doi: 10.1111/cas.15105

TABLE 2.

Univariate and multivariate Cox regression analyses of overall survival (OS) and progression‐free survival (PFS) in patients with oropharyngeal cancer

OS PFS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis

HR

(95% CI)

P value

HR

(95% CI)

P value

HR

(95% CI)

P value

HR

(95% CI)

P value
HPV16 DNA load
High/medium vs negative

5.53

(1.26‐24.2)

.023

5.67

(1.12‐28.82)

.036

8.36

(2.55‐27.42)

< .001

7.70

(2.04‐29.12)

.003
High/medium vs low

11.47

(2.56‐51.27)

.001

11.8

(2.19‐63.66)

.004

7.28

(2.05‐25.8)

.002

7.72

(1.91‐31.24)

.004
Sex
Female vs male

3.73

(0.89‐15.73)

.073

4.28

(1.32‐13.81)

.015

2.89

(0.88‐9.54)

.081
Age
<Mean vs >mean

1.29

(0.62‐2.69)

.493

1.40

(0.78‐2.52)

.266
Smoking
Never vs ever

1.09

(0.42‐2.88)

.855

1.73

(0.73‐4.10)

.212
Alcohol consumption
Never vs ever

0.59

(0.27‐1.32)

.199

1.14

(0.56‐2.32)

.711
Tumor localization

Nonpalatine tonsil vs

palatine tonsil

0.51

(0.24‐1.07)

.075

0.55

(0.30‐0.99)

.048

0.88

(0.48‐1.62)

.676
cT stage
Tis‐T1 vs T2‐T4

2.3

(0.55‐9.70)

.257

1.71

(0.61‐4.78)

.306
cN stage
N0‐N1 vs N2‐N3

1.20

(0.56‐2.58)

.645

0.94

(0.52‐1.70)

.838
Treatment

Surgery (with RT or CRT)

vs RT or CRT

0.86

(0.41‐1.80)

.686

1.09

(0.60‐1.95)

.785
p16
Negative vs positive

0.38

(0.16‐0.88)

.025

1.02

(0.40‐2.70)

.942

0.44

(0.23‐0.85)

.014

1.26

(0.60‐2.62)

.542
HPV16 physical status
Integrated vs episomal

0.30

(0.06‐1.57)

.155

0.46

(0.11‐1.93)

.286
Integrated vs mixed

0.56

(0.18‐1.77)

.324

0.59

(0.19‐1.87)

.370
Integrated vs no viral DNA

0.70

(0.25‐1.93)

.490

1.66

(0.64‐4.30)

.296

Bold indicates significant values.

Abbreviations: CI, confidence interval; cN, clinical nodal; CRT, chemoradiation therapy; cT, clinical tumor; HPV, human papillomavirus; HR, hazard ratio; RT, radiation therapy.